1Hakyemez B, Erdogan C, Ercan I, et al. High-grade and low-grade gliomas., differentiation by using perfusion MR imaging[J]. Clin Radiol,2005,60(4) -493-502. 被引量：1
2Provenzale J M, Wang G R, Brenner T, et al. Compari- son of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR ima- ging[J]. AJR, 2002,178(3) : 711-716. 被引量：1
5Zagzag D, Friedlander D R, Dosik J, et al. Tenascin-C expression by angiogenic vessels in human astrocyto- mas and by human brain endothelial cells in vitro[J]. Cancer Res,1996,56(2) -182-189. 被引量：1
6Warmuth C, Gunther M, Zimmer C. Quantification of blood flow in brain tumors:comparison of arterial spin labeling and dynamic susceptibility-weighted contrast- enhanced MR Imaging [J]. Radiology, 2003,228 (2) : 523-532. 被引量：1
7Detre J A, Alsop D C. Perfusion magnetic resonance imaging with continuous arterial spin labeling:methods and clinical applications in the central nervous system [J]. Eur J Radiol,1999,30(2) :115-124. 被引量：1
8Golay X A, Hendrikse J E, Lim T C, et al. Perfusion Imaging Using ASL[J]. Magn Reson Imag, 2004, 15 (1) :10-27. 被引量：1
2[3]Cha S, Knopp E, Johnson G, et al. Intracranial mass lesions: dynamic contrast - enhanced susceptibility - weighted echo - planar perfusion MR imaging. Radiology 2002; 223:11 ～ 29 被引量：1
3[4]Sun J, Jae H, Young M, et al. Perfusion MR imaging in gliomas:comparison with histologic tumor grade. Korean J Radiol 2001; 2:1～7 被引量：1
4[5]Knopp E, Cha S, Johnson G, et al. Glial neoplasmas: dynamic contrast - enhanced T2 * - weighted MR imaging. Radiology 1999;211: 791 ～ 798 被引量：1
5[6]Aronen H, Gazit I, Louis D, et al. Cerebral blood volume maps of glomas: comparison with tumor grade and histologic findings. Radiology 1994; 191: 41 ～ 51 被引量：1
6[7]Burger P, Vogel F, Green S, Strike T. Glioblastoma multiform and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 1985; 56:1106 ～ 1111 被引量：1
7[8]Wesseling P, Ruiter D, Burger P. Angiogenesis in brain tumors:pathological and clinical aspects. J Neurooncol 1997;32:253～ 265 被引量：1
8[9]Plate K, Mennel H. Vascular morphology and angiogenesis in glial tumours. Exp Toxic Pathol 1995; 47:89 ～ 94 被引量：1
9[1]Villringer A,Rosen BR,Belliveau JW,et al.Dynamic imaging with lanthanide chelates in normal brain:contrast due to magnetic susceptibility effects[J].Magn Reson Med,1998,6(2):164-174. 被引量：1
10[2]Cha S,Knopp EA,Johnson CT,et al.Dynamic contrast-enhamed T2*-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin[J].AJNR,2000,21(5):881-890. 被引量：1
4Asthagiri A R,Pouratian N,Sherman J,et al.Advances in brain tumor surgery[J].Neurologic clinics,2007,25(4):975-1003. 被引量：1
5Silvani A,Eoli M,Salmaggi A,et al.Phase II trial of cisplatin plus temozolomide,in recurrent and progressive malignant glioma patients[J].Journal of Neurooncology,2004,66(1-2):203-208. 被引量：1
6Eisenhauer E A,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].European journal of cancer,2009,45(2):228-247. 被引量：1
7Tuominen R,Jewell R,van den Oord J J,et al.MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma[J].International Journal of Cancer,2015,136(12):2844-2853. 被引量：1
8Valera E T,Machado H R,Santos A C,et al.The use of neoadjuvant chemotherapy to achieve complete surgical resection in recurring supratentorial anaplastic ependymoma[J].Child's Nervous System,2005,21(3):230-233. 被引量：1
